Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 598

Results For "IP"

10497 News Found

Govt. exhorts doctors to prescribe generic gedicines
Policy | July 31, 2023

Govt. exhorts doctors to prescribe generic gedicines

More than 9600 Pradhan Mantri Bhartiya Janaushadhi Kendras have been set up covering all districts of the country to promote generic medicines at affordable prices


AiMeD expresses dismay over FICCI’s ‘Un-Make in India’ drive
News | July 29, 2023

AiMeD expresses dismay over FICCI’s ‘Un-Make in India’ drive

Unfortunate to see PM’s ‘Make in India’ dream being bulldozed


Market success of Novo Nordisk’s obesity drug likely to be delayed in Japan, says GlobalData
News | July 29, 2023

Market success of Novo Nordisk’s obesity drug likely to be delayed in Japan, says GlobalData

In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1


Upsurge in pink eye conjunctivitis cases in the country
Healthcare | July 29, 2023

Upsurge in pink eye conjunctivitis cases in the country

Take proper precautions and seek timely treatment!


Dr. Reddy's Laboratories Q1 FY2024 consolidated PAT jumps to Rs. 1402.5 Cr
News | July 28, 2023

Dr. Reddy's Laboratories Q1 FY2024 consolidated PAT jumps to Rs. 1402.5 Cr

The company has reported total income of Rs. 6738.4 crores during the period ended June 30, 2023


Astec LifeSciences posts consolidated Q1FY24 loss at Rs. 8.19 Cr
News | July 28, 2023

Astec LifeSciences posts consolidated Q1FY24 loss at Rs. 8.19 Cr

Astec LifeSciences has reported total income of Rs. 144.55 crores during the period ended June 30, 2023


Laurus Labs posts decline in Q1FY24 consolidated PAT to Rs. 24.85 Cr
News | July 28, 2023

Laurus Labs posts decline in Q1FY24 consolidated PAT to Rs. 24.85 Cr

The company has reported total income of Rs. 1185.39 crores during the period ended June 30, 2023


Dr. Lal Path Labs Q1FY24 consolidated PAT up at Rs. 82.6 Cr
News | July 28, 2023

Dr. Lal Path Labs Q1FY24 consolidated PAT up at Rs. 82.6 Cr

Dr. Lal Path Labs Ltd. has reported total income of Rs. 555.4 crores during the period ended June 30, 2023


Ajanta Pharma's Q1 FY24 consolidated PAT up at Rs. 208.12 Cr
News | July 28, 2023

Ajanta Pharma's Q1 FY24 consolidated PAT up at Rs. 208.12 Cr

The company has reported total income of Rs. 1052.79 crores during the period ended June 30, 2023


Biocon Foundation releases 2nd edition of consensus guidelines for head & neck cancer
News | July 28, 2023

Biocon Foundation releases 2nd edition of consensus guidelines for head & neck cancer

Marks the World Head & Neck Cancer Day at the OCTF Conference